Additional ADCs currently under investigation for the treatment of CLDN18.2-positive G/GEJ cancer are included in Table 2 [67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86]. This evidence concerns the gene CLDN18 and cancer.